ClinicalTrials.gg
RecruitingNCT05489068Updated Nov 2, 2026

Motivational Interviewing at Intake vs Intake as Usual on Client Engagement in Addiction Treatment

An interventional study of Motivational Interviewing at Intake (MII) and Intake as Usual (IAU) in Substance-Related Disorders and Treatment Adherence, sponsored by University of New Mexico. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by University of New Mexico · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Mar 2022, registered Jul 2022).
  • Started Mar 2022; still recruiting 4 years 8 months later.
Updated Nov 2, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,589 studies in Substance-Related Disorders with a site in United States — 249 open to participants now, 313 under way, 4 of them phase 3. Substance-Related Disorders · United States.

Planned enrollment
557th of 1,447
150 · median 104
Started
2022
with 75 others
No phase
958 of 1,589
192 open now
Primary completion
2026-12
later than 79 of 312 live
Registered
1,237th of 1,589
by date

Among the 1,589 studies in Substance-Related Disorders with a site in United States, this one is the 557th largest by planned enrollment of the 1,447 interventional ones that give a count, is one of 76 that started in 2022, is one of 958 with no phase, reaches primary completion later than 79 of the 312 other live ones, and was the 1,237th registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

249 of the 1,589 studies in Substance-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

244 more — sign in →

All 249 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,589 studies in Substance-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

This K23 study is an effectiveness-implementation hybrid type I design to determine the effectiveness of Motivational Interviewing at Intake (MII), relative to intake-as-usual on client engagement and mechanisms of engagement among adults seeking outpatient addiction treatment. We also will obtain personnel feedback on the feasibility of implementing MII into standard practice by having personnel from the addiction treatment study sites complete implementation climate measures before Motivational Interviewing (MI) training and post-clinical trial, as well as an individual interview on implementation feasibility post-trial.

03

Conditions studied

  • Substance-Related Disorders
  • Treatment Adherence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (client participants):

  • English-speaking adults seeking treatment for alcohol or other drug use at one of two outpatient addiction treatment programs
  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures
  • Physically withdrawn from alcohol or other drugs

Inclusion Criteria (personnel participants):

  • English-speaking adults currently employed at one of the two outpatient addiction treatment programs
  • Provision of electronic informed consent

Exclusion Criteria (client participants):

  • Experiencing severe withdrawal symptoms
  • Actively psychotic, manic, and/or suicidal

Exclusion Criteria (personnel participants):

  • current position: facility owner or clinical director
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Motivational Interviewing at Intake (MII)

    Clients allocated to the MII condition will receive a 90-minute pure Motivational Interviewing (MI) session.

    Behavioral: Motivational Interviewing at Intake (MII)

  • Active comparator
    Intake as Usual (IAU)

    Clients allocated to the IAU condition will receive the 90-minute standard assessment that is delivered to all clients entering intensive outpatient program (IOP)/outpatient program (OP).

    Behavioral: Intake as Usual (IAU)

Interventions

  • BehavioralMotivational Interviewing at Intake (MII)

    The MII will involve a goal-oriented and collaborative conversation about why the client wants treatment now, and how treatment might fit with his/her most important values. The provider will use open questions, reflective listening and autonomy support in a flexible, non-authoritative manner. Rather than asking specific questions in different life domains, the provider will explore with the client their desires, abilities, reasons, and needs for treatment, how treatment fits with their values, and what successful treatment looks like to them. The client's language about change will be strategically reinforced to increase its frequency and strength across the session.

  • BehavioralIntake as Usual (IAU)

    In line with the American Society of Addiction Medicine (ASAM) guidelines, the IAU condition involves a semi-structured interview of the client's psychosocial history and clients answer a series of questions in the following domains: support system, living situation, educational, occupational, family, and medical history.

06

What researchers measure

Primary outcomes

  1. Number of participants who attended the first outpatient treatment program session based on electronic medical record review

    Treatment entry is determined by review of electronic medical record of whether clients attended their first scheduled treatment session

    Time frame: up to 36 weeks

  2. Number of treatment sessions attended during the three-month outpatient treatment program based on electronic medical record review

    Number of treatment sessions that clients attend is determined by review of electronic medical record and calculating number of treatment sessions attended.

    Time frame: up to 36 weeks

  3. Number of participants who completed the three-month outpatient treatment program based on electronic medical record review

    Completion of the three-month outpatient treatment program is determined by review of electronic medical record

    Time frame: up to 36 weeks

Secondary outcomes

  1. Change from baseline in client readiness to enter treatment on the University of Rhode Island Change Assessment Scale (URICA) at 1 hour post-intake

    The URICA is a validated, self-report measure of client readiness for treatment engagement. Possible scores range from 32 to 160 with higher scores indicative greater readiness to enter treatment. Change = (Hour 1 score - Baseline Score).

    Time frame: baseline and 1 hour post-intake

  2. Score on therapeutic alliance on the Working Alliance Inventory (WAI) at 1-hour post-intake

    The WAI is a validated, self-report measure of client perceptions of the therapeutic process by assessing three sub scales: Goals, Bond, and Tasks. Possible scores on sub scales range from 12 to 84 with higher scores indicative of better therapeutic alliance.

    Time frame: 1 hour post-intake

Other outcomes

  1. Change from baseline in organizational readiness to change on the Texas Christian University-Organizational Readiness to Change (TCU-ORC) at 1 year

    The TCU-ORC is a validated, self-report measure of personnel perceptions of their organization's readiness and willingness to make changes. Possible scores range from 125 to 625 with higher scores indicative of more readiness to change. Change = (Year 1 score - Baseline Score).

    Time frame: baseline and 1 year

  2. Change from baseline in organizational readiness to change on the Readiness for Organizational Change (ROC) at 1 year

    The ROC is a validated, self-report measure of personnel perceptions of their organization's readiness to change. Possible scores range from 25 to 155 with higher scores indicative of more readiness to change. Change = (Year 1 score - Baseline Score).

    Time frame: baseline and 1 year

  3. Change from baseline in organizational capability to change on the Change Process Capability Questionnaire (CPCQ) at Year 1

    The CPCQ is a validated, self-report measure of personnel perceptions of of their organization's capability to change. Possible scores range from 1 to 132 with higher scores indicative of more capability to make changes in the organization. Change = (Year 1 score - Baseline Score).

    Time frame: baseline and 1 year

07

Study locations

1 of 1 sites recruiting
  • UNM Psychology Clinic
    Albuquerque, New Mexico 87131, United States
    Recruiting
08

References and documents

Publications

  • Hurlocker MC, Moyers TB, Hatch M, Curran G, McCrady B, Venner KL, Witkiewitz K. Effectiveness and feasibility of a motivational interviewing intake (MII) intervention for increasing client engagement in outpatient addiction treatment: an effectiveness-implementation hybrid design protocol. Addict Sci Clin Pract. 2023 Oct 21;18(1):63. doi: 10.1186/s13722-023-00412-y. PubMed 37865777 ↗

Individual participant data

Plan to share: Yes — Individual participant data that underlie results reported in a peer-reviewed publication, after deidentification (text, tables, figures, and appendices). Session audio recordings will not be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will become available starting in January 2025

Access criteria: Researchers who provide a methodologically sound proposal will have access to the data. A data use agreement will be required, signed by the requesting investigator and their Authorized Organization Representation (AOR)/Signing Official (SO)

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 56 months after the start.

Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 56 months is above that.

Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2022
First posted
Aug 5, 2022
StartActual
Mar 16, 2022
Primary completionEst.
Dec 1, 2026was Oct 2026
CompletionEst.
Dec 1, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2026→Dec 1, 2026
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Oct 1, 2026→Dec 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05489068
Responsible party
Sponsor
First posted
Aug 5, 2022
Start date
Mar 16, 2022
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Nov 2, 2026

Study contacts

Margo Hurlocker, PhD
Contact
mhurlocker@unm.edu
(505) 596-0578
Margo Hurlocker, PhD
principal investigator · University of New Mexico

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion